Skip to main content

View full-text article in PMC

. 2015 Mar;352(3):529–540. doi: 10.1124/jpet.114.221572

TABLE 2.

Ability of sulfa drugs to inhibit sepiapterin reduction and redox cycling by SPR

Inhibitor	Sepiapterin Reduction^a		Redox Cycling
Inhibitor	Inhibition Type	IC₅₀	Inhibition Type	IC₅₀
		nM		μM
Antibacterial
Sulfasalazine	Noncompetitive	31	Noncompetitive	0.53
Sulfathiazole	Noncompetitive	62	Noncompetitive	8.02
Sulfapyridine	Noncompetitive	141	Noncompetitive	19.41
Sulfamethoxazole	Noncompetitive	180	Noncompetitive	10.97
Antidiabetic
Chlorpropamide	Noncompetitive	120	Noncompetitive	0.37
Glibenclamide	Noncompetitive	340	Noncompetitive	1.11
Tolbutamide	Noncompetitive	510	Noncompetitive	4.58

^{^a}

Sepiapterin reduction and redox cycling were measured as described in Materials and Methods. For redox cycling assays, 200 μM menadione was used.